Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-352-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees78
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable
Pfenex (NASDAQ:PFNX) Frequently Asked Questions
What is Pfenex's stock symbol?
Pfenex trades on the NASDAQ under the ticker symbol "PFNX."
How were Pfenex's earnings last quarter?
Pfenex Inc. (NASDAQ:PFNX) released its quarterly earnings results on Thursday, November, 7th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.09. The business had revenue of $15.25 million for the quarter, compared to the consensus estimate of $14.80 million. View Pfenex's Earnings History.
When is Pfenex's next earnings date?
What is the consensus analysts' recommendation for Pfenex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.
Has Pfenex been receiving favorable news coverage?
Media coverage about PFNX stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfenex earned a news impact score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Pfenex.
Who are some of Pfenex's key competitors?
Some companies that are related to Pfenex include Clinuvel Pharmaceuticals (CUV), Mesoblast (MSB), Concordia International (CXR), Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), TELIX Pharmaceutical (TLX), Biotest (BIO), CEL-SCI (CVM), Cel-Sci (CVM), Neptune Wellness Solutions (NEPT) and ProMetic Life Sciences (PLI).
What other stocks do shareholders of Pfenex own?
Who are Pfenex's key executives?
Pfenex's management team includes the folowing people:
- Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
- Ms. Susan A. Knudson, Sr. VP & CFO (Age 55)
- Mr. Patrick K. Lucy, Sr. VP & Chief Bus. Officer (Age 51)
- Dr. Shawn A. Scranton Pharm. D, Sr. VP & COO (Age 55)
- Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
How do I buy shares of Pfenex?
Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pfenex's stock price today?
One share of PFNX stock can currently be purchased for approximately $12.30.
How big of a company is Pfenex?
What is Pfenex's official website?
How can I contact Pfenex?
The company can be reached via phone at 858-352-4400.
MarketBeat Community Rating for Pfenex (NASDAQ PFNX)
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
